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Abstract
The thyrotropin receptor (TSHR) is a G protein-coupled receptor (GPCR) that is member of
the leucine-rich repeat subfamily (LGR). In the absence of crystal structure, the success of
rational design of ligands targeting the receptor internal cavity depends on the quality of the
TSHRmodels built. In this subfamily, transmembrane helices (TM) 2 and 5 are character-
ized by the absence of proline compared to most receptors, raising the question of the struc-
tural conformation of these helices. To gain insight into the structural properties of these
helices, we carried out bioinformatics and experimental studies. Evolutionary analysis of
the LGR family revealed a deletion in TM5 but provided no information on TM2. Wild type
residues at positions 2.58, 2.59 or 2.60 in TM2 and/or at position 5.50 in TM5 were sub-
stituted to proline. Depending on the position of the proline substitution, different effects
were observed on membrane expression, glycosylation, constitutive cAMP activity and
responses to thyrotropin. Only proline substitution at position 2.59 maintained complex gly-
cosylation and high membrane expression, supporting occurrence of a bulged TM2. The
TSHR transmembrane domain was modeled by homology with the orexin 2 receptor, using
a protocol that forced the deletion of one residue in the TM5 bulge of the template. The sta-
bility of the model was assessed by molecular dynamics simulations. TM5 straightened dur-
ing the equilibration phase and was stable for the remainder of the simulations. Our data
support a structural model of the TSHR transmembrane domain with a bulged TM2 and a
straight TM5 that is specific of glycoprotein hormone receptors.
Introduction
The thyroid stimulating hormone or thyrotropin (TSH) has a major role in the growth and
function of the thyroid gland that produces the thyroid hormones T3 (triiodothyronine) and
T4 (tetraiodothyronine or thyroxine) [1]. TSH acts by binding to its cognate receptor, TSHR,
which is a member of the Leucine-rich repeat subfamily (LGR) of G protein-coupled receptors
(GPCRs) [2]. The LGR subfamily includes, among others, TSH, FSH (follitropin) and LH/CG
(lutropin/chorionic gonadotropin) receptors. The LGR receptors possess a seven
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transmembrane helix (TM) domain typical of GPCRs, a large N-terminal domain consisting of
a leucine-rich repeat domain (LRR), and a hinge region linking the LRR domain to the trans-
membrane domain. The LRR domain is the main binding site of the glycoprotein hormones,
whereas the hinge and the transmembrane domain are involved in signal transduction.
Low molecular weight ligands targeting TSHR have been developed and can act as agonists
or antagonists [3–7]. Contrary to thyrotropin, they bind to the internal cavity of the transmem-
brane domain. They have therapeutic potential for diseases where the TSHR signal is disturbed,
such as Graves’ disease, or in thyroid cancer as an alternative to recombinant human TSH for
radioiodine ablation of thyroid remnants or metastases. Currently, crystal structures have been
resolved for the ectodomain of TSHR [8] and FSHR [9], but not for their transmembrane
domain. Therefore, the rational design of drugs targeting the transmembrane domain of TSHR
is highly dependent on the quality of the model(s) used.
The GPCR crystal structures resolved to date illustrate that, although the general fold of the
TM domain is conserved within the GPCR superfamily, each receptor displays distinct local
structural features, in particular for helical distortions [10]. Helical distortions are frequent in
GPCRs and are often stabilized by proline residues [11]. Two main distortions are possible to
avoid steric clashes between the pyrole ring of proline and helix backbone: kinks in which pro-
line ring is close to the carbonyl groups at positions -3 and -4, and bulges in which the proline
ring is close to the carbonyl groups at positions -4 and -5, because of an additional residue in
the helical turn preceding proline [12, 13]. Class A GPCRs possess two highly conserved pro-
line residues in TM6 and TM7. They are part of the CWXP and NPXXY motifs, in TM6 and
TM7, respectively, and have an important functional role in activation [11, 14]. Two proline
residues in TM2 and TM5 are also present in about 80% of class A GPCRs [15]. The proline
residues in TM2 can be found at positions 2.58, 2.59 or 2.60 (Ballesteros’ numbering [16]),
with respective weight of 40, 37 and 3% [17] whereas, in TM5, only position 5.50 is observed.
The GPCR crystal structures resolved to date reveals a variety of structures for TM2 and
TM5 that may be related to their proline pattern. TM2 is bulged in P2.59 receptors, such as
β2AR (β2 adrenergic receptor) [18] and OX2 (orexin receptor 2) [19], and in P2.60 receptors
such as squid rhodopsin [20] whereas it is kinked in P2.58 receptors, such as CXCR4 (CXC
chemokine receptor type 4) [21], P2Y1 (P2Y purinoceptor 1) [22] and P2Y12 (P2Y purinocep-
tor 12) [23]. When no proline is present in TM2, the helix may be bulged such as in bovine rho-
dopsin [24] and ACM (muscarinic acetylcholine receptors) [25], or straight such as in S1P1R
(sphingosine 1 receptor) [26]. TM5 is bulged in receptors with a proline residue at position
5.50, such as rhodopsin [24], β2AR [18], OX2 [19], CXCR4 [21] and P2Y1 [22], whereas TM5
is straight in receptors with no proline in TM5, such as S1P1R [26] and P2Y12 [23]. Fig 1 rep-
resents the crystal structures of S1P1R, with straight TM2 and TM5, and of OX2, with bulged
TM2 and TM5.
LGR receptors do not possess proline residues in TM2 and TM5, which prevents a priori
prediction of the structures of these helices. However, modelling TSHR with straight or bulged
TM2 and TM5 will result in a frame shift of their extracellular sides, resulting in models with
different putative binding sites for small ligands. A previous study carried out by Kleinau and
co-workers [27] supports the hypothesis of a straight TM5, consistent with the structures of
S1P1R and P2Y12. Here, we investigate the structure of TM2 with a set of TM2 mutants. Pro-
line residues were introduced at different positions in TM2 (2.58, 2.59 and 2.60) alone or in
combination with a proline mutation at position 5.50 in TM5, then the functional properties of
the mutated receptors were analyzed. Coupled with sequence analysis of the LGR subfamily
and to dynamics homology modelling [28], our data support a model of TSHR with a straight
TM5 and a bulged TM2.
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Materials and Methods
Materials
DMEM/Ham’s F12 (Dulbecco’s Modified Eagle’s Medium/Ham’s F12) was purchased from
PAA Laboratories (Pasching, Austria). Fetal calf serum was purchased from Biowest (Nuaille,
France). Glutamine, penicillin and streptomycine were purchased from Lonza (Verviers, Bel-
gium). Polyethylenimine (PEI) was purchased from Polysciences (Warrington, United King-
dom). The pcDNA3.1 plasmid containing the cDNA for human TSHR with a rho tag sequence
at the N-terminus was kindly provided by Dr S. Costagliola (Université Libre de Bruxelles,
Bruxelles, Belgium) [29]. Mouse anti-rho tag primary antibodies ORI2156 [29] were kindly
provided by Dr P. Hargrave (University of Florida, Gainesville, FL). FITC-conjugated goat
anti-mouse secondary antibodies were purchased from Dako (Courtaboeuf, France), and goat
anti-mouse IgG secondary antibodies HRP 31430 were purchased from Thermoscientific
(Waltham, USA). Luminol was purchased from Santa Cruz Technology (Dallas, USA). EndoH
and PNGaseF were purchased from Promega (Fitchburg, USA). Thyrotropin from bovine pitu-
itary (bTSH) was obtained from Sigma-Aldrich (St Louis, United-States). All other reagents
were purchased from Sigma-Aldrich.
Site-directed mutagenesis
TSHR mutants were generated by GeneCust (Dudelange, Luxembourg), from the pcDNA3.1
plasmid containing the rho tag TSHR sequence. The rho tag includes 19 amino acids from
the N-terminus of rhodopsin that have been linked to the N-terminus of TSHR [29]. All the
mutated plasmids were sequenced for control.
Fig 1. Structure of selected GPCRs. Ribbon representation of the crystal structure of (a) S1P1R (PDB # 3V2Y) and (b) OX2 (PDB # 4S0V). TM2 and TM5
are green. Positions 2.59 and 5.50 are blue. The proline residues at positions 2.59 and 5.50 in OX2 are shown as sticks. Ovals indicate the positions of the
helical distortions, if any.
doi:10.1371/journal.pone.0142250.g001
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Cell culture and transfection
HEK-293 cells were grown in DMEM/Ham's F12 medium supplemented with 10% fetal calf
serum, 1% glutamine and 1% penicilline-streptomycine at 37°C in a humidified 5% CO2 incu-
bator. Cells were transiently transfected in 6-well (222 222 cells/well) or 96-well (11 111 cells/
well) plates with the plasmid constructs (246 ng total for 106 cells) using PEI (738 ng of PEI for
106 cells) and allowed for platting. The medium was changed 20 hours after transfection.
Flow cytometry measurements
The cell surface expression was determined by flow cytometry. Two days after the transfection,
cells were detached from the 6-well plates using PBS/EDTA (8mM). Suspended cells were cen-
trifuged to discard supernatant. The following steps were performed in FACS buffer (PBS con-
taining BSA 0.1%). Cells were incubated for 30 min with a 1:10 mouse anti-rho tag antibody,
then they were washed once and incubated for 30 min with a 1:20 FITC-conjugated goat anti-
mouse antibody and with propidium iodide 5 μg/ml to label damaged cells. From this part,
cells were maintained at 0°C. Cells were washed and resuspended in FACS buffer. The fluores-
cence signal of 104 cells/tube was measured. Cells transfected with empty pcDNA3.1 plasmid
were used as a negative control. Flow cytometry measurements were performed on FACSCali-
burTM from BD Biosciences (Franklin Lakes, USA). Propidium iodide positive cells were
excluded. Expression of mutated receptors is given as a percentage of the wild type control.
FACS measurements were also performed on cells permeabilized with saponin (0.1 mg/mL).
Determination of the glycosylation states
Glycosylation states of TSHR were analysed by Western blots. Two days after transfection, cells
seeded in 6-well plates were washed with cold PBS, and lysed with SDS buffer (SDS 1%, Tris
10mM, Na Ortovanadate 1mM, Na Fluoride 10mM, antiprotease). Insoluble debris were
removed by centrifugation (15 min at 13000 g). The samples were run on 8% acrylamide gel
and probed with 1:10000 mouse anti-rho tag antibody. The receptors were visualized with a
1:5000 goat anti-mouse antibody and Luminol (60 seconds exposure time). The ratio of the dif-
ferent bands was determined with the Fujifilm Luminescent Image Analyzer LAS-3000.The
glycosylation forms of the bands were determined by glycosidase treatments. Endoglycosidase
H (EndoH) and Peptide-N-Glycosidase F (PNGaseF) were used according to the supplier’s
protocol, overnight, before running. EndoH cleaves within the chitobiose core of high mannose
and some hybrid oligosaccharides. PNGaseF cleaves between the innermost GlcNAc and Asn
residues of high mannose, hybrid, and complex oligosaccharides N-linked to a protein.
cAMP accumulation assay for TSH dose-response
The accumulation of intracellular cAMP was measured with the GloSensor cAMP Assay from
Promega (Fitchburg, USA). The pGloSensorTM-22F cAMP plasmid was transfected simulta-
neously with the receptor plasmid. Two days after the transfection, cells from the 96-well plates
were pre-equilibrated with GloSensorTM cAMP Reagent for two hours. Then bTSH was added
and luminescence was measured after 30 min. Cells transfected with empty pcDNA3.1 plasmid
were used as a negative control. Luminescence assays were performed on Synergy 3TM from
BioTek (Vermont, USA).
Constitutive cAMP activity of TSHR
To compare the constitutive activity of the wild type (WT) and mutated receptors for cAMP
accumulation, the cells were transfected with increasing amounts of the pcDNA3.1 plasmid
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containing WT or mutated TSHR sequence, resulting in different cell surface expression of the
receptors. The total plasmid concentration was kept constant by addition of empty pcDNA3.1
plasmid. Rolipram (25.10−6 ng/μl) was added 30 min before luminescence measurement of
basal cAMP concentration. Then, the linear regression of the luminescence signal (basal
cAMP) as a function of the surface expression of the receptor measured by flow cytometry was
determined with R (www.r-project.org). We used the luminescence of the cells transfected with
the empty pcDNA3.1 plasmid as the origin. For the statistical tests, the slopes of the lumines-
cence vs the fluorescence signal of the mutated receptors were determined relatively to the WT
control, set to 1, then Student’s t-tests were used for statistical analysis.
Intracellular Ca2+ measurement
Two days after the transfection, cells in 96-well plate were incubated for one hour at room tem-
perature with reduced light with Fura-2-acetoxymethyl ester (Fura-2 AM, 2μM) in HBSS buffer
(CaCl2 2.5mM, MgCl2 1mM, Hepes 5mM et BSA 0.5%, pH = 7.3). Cells were washed twice,
and then incubated for one hour with HBSS buffer before fluorescence measurement. Cells
transfected with empty pcDNA3.1 plasmid were used as a negative control. The fluorescence
measurements were performed with a FlexStation 3 fromMolecular Devices (Silicon valley,
USA). The fluorescence emitted by Fura-2 AM at 510 nm was measured upon excitation at 340
nm (Ca2+ bound Fura-2) and 380 nm (Ca2+ free Fura-2). The ratio of the fluorescence signals
and the resulting AUC (area under the curve) were then calculated with GraphPad Prism
(GraphPad Software, San Diego, USA).
Data and statistical analysis
All experiments were performed in triplicates or more. For Western blots, the areas of relative
density plots for each condition were extracted with ImageJ (www.imagej.net). The percentage
of complex glycosylated receptors on total receptors (complex glycosylated receptors + high
mannose-glycosylated receptors) for each condition was then compared to the wild type with
the Student’s t test. P values less than 0.05, 0.01 and 0.001 are shown with 1 (), 2 () and 3
() asterisks, respectively.
Sequence analysis
The non-redundant sets of the LGR sequences fromH. sapiens, D. rerio, C. intestinalis, B. Flori-
dae, D.melanogaster, C. elegans and N. vectensis were prepared as described elsewhere [17].
Multiple sequence alignment (MSA) was carried out with Clustal X 2.1 [30] and manually
refined with Genedoc [31]. The MSA is available as Supporting Information (S1 File). Boot-
strapped (500 replicates) neighbor-joining (NJ) trees were built with the MEGA 5 software
[32], from the alignment of the transmembrane helices. Positions in the transmembrane helices
were numbered according to Ballesteros’ nomenclature [16]. N432, D474, R519, W546, P639,
and P675 of TSHR were used as the reference position n.50 of each helix n, except TM5, for
which Y601 of TSHR, corresponding to the highly conserved Y5.58, was used as the reference.
Molecular modelling and dynamics simulations
The transmembrane domain of human TSHR (residues D410 to S694) was modeled with
MODELLER 9v8 [33], using the crystal structure of the orexin receptor 2, OX2 (PDB # 4S0V)
[19] as a template. Peptide receptors are better suited templates to model peptide/protein
receptors [34]. OX2 was chosen among available structures of peptide receptors because it pos-
sesses bulges in both TM2 and TM5, and the Y5.38 and Y5.58 patterns in TM5. The insertion
Insights into the TSHR Transmembrane Domain
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in the extracellular loop (ECL) 1 of TSHR was modeled as a helix based on secondary structure
prediction using Jpred3 [35]. The backbone of the ECL2 hairpin was positioned in the vicinity
of the K660 side chain (position 7.35) by adding distance constraints to take into account
experimental data [36]. TM2 of wild type TSHR was modeled with a bulge similar to that
observed in OX2 whereas TM5 was modeled with a deletion at position 5.45. Fifty models were
generated and refined by simulated annealing. The models were classified using the MODEL-
LER objective function score. The positions and nature of the violations of the top three models
were analysed, to determine the “best”model for molecular dynamics simulations (MD).
MD simulations in explicit membrane environment were carried out using NAMD v2.8
MD software [37]. The “best”model was prepared for simulations in explicit membrane envi-
ronment using the Charmm Gui interface [38, 39]. Models were embedded in a palmitoyl-
oleoyl-phosphatidyl-choline (POPC) lipid bilayer and solvated in a TIP3P model for water
molecules [40], with all atoms represented explicitly. Chloride ions were added to the system to
achieve electro neutrality. The CHARMM27 (with cross-term correction for backbone dihedral
angles) and CHARMM36 parameter sets were used for the protein [41, 42] and for POPC lip-
ids [43, 44], respectively. The entire assembly was then subjected to energy minimization for
10000 steps to remove close contacts between receptor atoms and solvent or lipid layers. Equili-
bration of protein–membrane system was carried out with a protocol modified from that
developed by Jo et. al [45]. The protocol included six interlinked equilibration steps in which
harmonic restraints were gradually taken off to achieve a smooth relaxation, for a total of
1.7 ns. In the first three equilibration steps, the NVT ensemble at 310 K and time step of 1 fs
were used. During the next equilibration steps and the production phase of 60 ns, the system
was run at constant temperature (310 K) and pressure (1 atm), using a 2 fs time step for inte-
gration. The SHAKE algorithm was applied to all bonds involving hydrogens. The Particle
Mesh Ewald method (PME) was used to calculate the electrostatic contribution to non-bonded
interactions with a cutoff of 12 Å. The cutoff distance of the van der Waals interaction was 12
Å. The equilibration steps were carried out locally on a NEC 140Rb-4 server. The production
steps were carried out on the E-Biothon cloud platform (www.e-biothon.fr). Trajectories were
analyzed with VMD software [46]. H-bonds were measured with HBPLUS [47], Bend angles
were measured using in-house script [13]. PYMOL (DeLano Scientific LLC, San Franscisco,
USA) was used for figure preparation.
Results
Phylogenetic analysis indicates a deletion in TM5 of TSHR
The analysis of class A GPCRs from seven species (two vertebrates: H. sapiens and D. rerio, two
chordates: C. intestinalis and B. Floridae, one insect: D.melanogaster, one nematode: C. elegans,
and one cnidarian: N. vectensis) led to a set of 52 non-redundant sequences of LGR receptors
(sequence identities< 90%). The NJ tree based on the alignment of the transmembrane helices
indicates three sub-groups (Fig 2A). The first sub-group includes receptors similar to the glyco-
protein hormone receptors and to LGR4-6. The second sub-group includes receptors similar to
the relaxin/insulin-like family peptide receptors 1 and 2 (RXFP1/2). These two groups are pres-
ent from cnidarians to vertebrates. The third sub-group corresponds to an extension of the
LGR subfamily specific to C. intestinalis. Analysis of these sequences reveals that the receptors
from group 2 have a tyrosine residue at position 5.38, whereas the receptors from groups 1 and
3 have a tyrosine residue at position 5.39 (S1 File).
Comparison with other class A GPCR sequences indicates that the Y5.38 pattern is widely
present in peptide and amine receptors and in opsins. Conversely, the Y5.39 pattern is present
in the MEC subfamily (melanocortin, sphingosine 1 phosphate and cannabinoid receptors).
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The alignment of the TM5 sequences of LGR receptors with conserved N-terminal Y5.38/Y5.39
and C-terminal Y5.58 motifs requires a gap (Fig 2B for human sequences and S2 File for the
entire set). The best location for the deletion is position 5.45 because it maintains hydrophobic
pattern observed between the N-terminal Y5.38/Y5.39 and the conserved N5.47 residue. This
phylogenetic analysis supports a model in which glycoprotein hormone receptors evolved from
the deletion of one residue in the bulge of TM5 in an ancestral LGR receptor and corroborates
the straight structure of TM5 in TSHR proposed by Kleinau and co-workers [27].
Fig 2. Evolution of LGR receptors. (a) NJ tree of 52 LGR receptors from seven species. The Y5.38 and Y5.39 patterns are indicated by an open and a
closed symbol, respectively. (b) Sequence alignment of residues 2.50 to 3.25 and residues 5.38 to 5.58 of the human LGR receptors. The shading
corresponds to the alignment of the 52 sequences. Fully conserved positions are shaded in black, partially conserved or type-conserved positions are
shaded in dark grey (80% conservation) or light grey (60% conservation).
doi:10.1371/journal.pone.0142250.g002
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By contrast, TM2, TM3 and the connecting ECL1 are highly conserved, with no evidence of
insertion / deletion between the highly conserved D2.50 and C3.25 residues (Fig 2B), and the
alignment provides no information on the structure of TM2. In order to gain structural infor-
mation on TM2, we thus engineered proline mutants in TM2 positions where proline residues
may be found in class A GPCRs: 2.58, 2.59 or 2.60 [17]. We also engineered a single proline
mutant at position 5.50, for comparative purpose, and double proline mutants in TM2 and
TM5 to study the independence of the mutations in these two helices.
Cell surface expression and glycosylation are impaired for most mutants
except L2.59P TSHR
HEK-293 cells were transiently transfected with the pcDNA3.1 plasmid containing the
sequence of WT or mutated TSH receptors. The receptor expression was measured by flow
cytometry on intact and permeabilized cells (Fig 3). The L2.59 mutant had cell membrane
expression (130 ± 20%) similar to WT. However the cell membrane expression decreased to
about 40% of WT for the I2.60P and A5.50P mutants, to 20% of WT for the L2.58P mutant,
and to less than 10% for the double mutants (Fig 3A). In permeabilized cells (Fig 3B), the
amount of receptors observed were 60 ± 10% of WT for the L2.59P mutant, about 30% of WT
for the L2.58P, I2.60P and A5.50P mutants and about 15% of WT for the double mutants.
N-glycosylation is required for cell surface expression and activity of TSHR [48, 49]. The
glycosylated form(s) of WT and mutated receptors present in cells can be visualized using
Western blots (Fig 4). As previously observed by others [48], WT TSHR was detected as two
bands corresponding to a molecular weight of 120 and 95 kDa. Among the mutated receptors,
only the L2.59P mutant presented the same two bands as WT. The glycosylation states of these
forms were verified with the endoH and PNGaseF glycosidases (Fig 4). The 95 kDa form corre-
sponds to high mannose-glycosylated receptors that are endoH and PNGaseF-sensitive. The
Fig 3. Expression of the TSHRmutants. (a) Cell surface expression and (b) total cell expression of WT and mutated TSHRs, given as the percentage of
the wild type control, after transfection of HEK-293 cells by the same amount of TSHR coding pcDNA3.1 plasmid. Receptor expression was determined by
flow cytometry measurements of intact (a) or permeabilized cells (b). The histograms represent the mean ± SEM of at least 3 independent experiments, each
carried out in triplicates.
doi:10.1371/journal.pone.0142250.g003
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120 kDa form corresponds to complex glycosylated receptors that are endoH resistant and
PNGaseF-sensitive. The endoH resistant 120 kDa form represented 62 ± 7% of the total
amount of WT and 32 ± 3% of the L2.59P mutant. This high molecular weight form was not
detectable (< 4%)) for the other mutants that were present in the cells but only as a high man-
nose-glycosylated 95 kDa form. Absence of complex glycosylation did not prevent some of
these mutants to be addressed to the membrane (Fig 3A), in agreement with Nagayama et al.
[48]. The low membrane expression of the L2.58P mutant cannot be attributed to the absence
of complex glycosylation since this is also the case for the I2.60P and A5.50P mutants that have
total cell expression similar to the L2.58P mutant (Fig 4), implying specific blockage of most
L2.58P mutants at a quality control checkpoint during membrane targeting [50].
Single mutations have differential effect on TSHR activity
TSHR activates the cAMP pathway, both constitutively and upon TSH stimulation [51]. In a
first assay, we measured TSH induced cAMP activity for all mutants in HEK-293 cells trans-
fected with the same amount of TSHR coding pcDNA3.1 plasmid (Fig 5A). In this assay, the
constitutive activity of WT TSHR was observed as a very high baseline, which was not observed
for any mutant, including the L2.59P mutant. TSH induced a robust cAMP response for WT
and the L2.59P, I2.60P and A5.50P mutants. Conversely, the L2.58P mutant and the double
mutants did not induce cAMP accumulation in response to TSH. In spite of the low membrane
expression of the L2.58P mutant, its constitutive activity could be observed as a baseline signifi-
cantly above the baseline obtained with the plasmid control. This strongly suggests that the
absence of TSH induced cAMP accumulation corresponds to an impaired mechanism of acti-
vation by bTSH. For the double mutants, the response did not differ from the plasmid control.
This might be related either to impaired activation or to the very low membrane expression of
these mutants. In a second assay (Fig 5B), we adjusted the amounts of the pcDNA3.1 plasmid
coding for WT and single mutants to yield roughly the same level of membrane expression for
the different receptors (with the exception of the L2.58P mutant due to its low membrane
expression). In these conditions, the maximal activities were in the same range for the WT
receptor and the L2.59P, I2.60P and A5.50P mutants (80 ± 10% of the maximal activity
obtained with a 10-fold increase in the amount of the transfected plasmid containing the WT
Fig 4. Glycosylation status of the TSHRmutants. Typical western blots of WT and mutated TSHRs, representative of three independent experiments. The
identity of the bands was verified by treatment with endoH and PNGase. The band at 120 kDa corresponds to complex glycosylated receptors that are endoH
resistant and PNGaseF-sensitive. The band at 95 kDa corresponds to high mannose-glycosylated receptors that are endoH and PNGaseF-sensitive.
doi:10.1371/journal.pone.0142250.g004
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sequence). The EC50 of the mutants did not significantly differ fromWT with similar levels of
membrane expression (Table 1).
We measured the constitutive activity of WT and mutated receptors by the basal level of
cAMP observed at different levels of receptor membrane expression (Fig 6 and Table 1). For
Fig 5. TSH induced cAMP response of TSHRmutants. Typical dose-response curves of cAMP accumulation induced by TSH on HEK-293 cells
transfected with pcDNA3.1 plasmids encodingWT or mutated TSHRs. In (a), the cells were transfected with the same amount of TSHR coding plasmids,
leading to the cell membrane expression shown in insert. In (b), the cells were transfected with different amounts of TSHR coding plasmids to obtain similar
levels of cell surface expression, shown in insert. The total amount of pcDNA3.1 plasmids was kept constant by addition of empty plasmids. Receptor
symbols: closed circles, WT; closed down triangles, L2.58P; open squares, L2.59P; open triangles, I2.60P; closed diamonds, A5.50P; closed squares,
L2.58PA5.50P; closed triangles, P2.59PA5.50P; open diamonds, I2.60PA5.50P.
doi:10.1371/journal.pone.0142250.g005
Table 1. Functional characterisation of cAMP accumulation by the TSHRmutants.
TSHR Inducible activitya Relative constitutive activitye
EC50b Emaxc CSEd
WT 0.4 ± 0.2 80 ± 6 39 ± 4 1
L2.58P - - - 1.7 ± 0.3
L2.59P 0.8 ± 0.4 70 ± 4 27 ± 3 0.23 ± 0.05**
I2.60P 0.8 ± 0.2* 84 ± 3 23 ± 2 0.31 ± 0.08*
A5.50P 0.6 ± 0.2 88 ± 6 31 ± 2 0.26 ± 0.03**
a HEK-293 cells were transiently transfected with variable amounts of the pcDNA3.1 plasmid containing WT or mutated TSHRs, adjusted to yield similar
cell surface expression in order to minimize the effect of the receptor concentration on the measured parameters. The WTmax control was obtained by
transfecting HEK-293 cells with a 10 fold increase in the amount of pcDNA3.1 plasmid encoding WT TSHR. The data are given as the mean ± SEM of
three independent experiments, each carried out in triplicates.
b EC50 is expressed in mUI/ml. The EC50 for the WTmax control is 0.2 ± 0.1.
c Emax values are expressed as a percentage of the WTmax control.
d The cell surface expression (CSE) was quantiﬁed by ﬂow cytometry measurements. CSE levels are expressed as a percentage of the WTmax control
e The relative constitutive activity of the TSHR mutants was estimated from the ratio of the slopes in the linear regression of the basal cAMP level as a
function of the cell surface expression for mutated and WT receptors. The constitutive activity of the WT control is set to 1. The data are given as the
mean ± SEM of three independent experiments, each carried out in triplicates.
doi:10.1371/journal.pone.0142250.t001
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each mutant, a control with WT was made in the same experimental set. The ratio of the slopes
gives an estimate of the relative constitutive activities. A 3–4 fold decrease in the constitutive
activity was observed for the L2.59P, I2.60P and A5.50P mutants. This was not the case for the
L2.58P mutant whose constitutive activity was at least as high as that observed for WT receptor
(Table 1). The differences between the A5.50P mutant data reported by Kleinau et al. [27] and
here might result from the higher level of cell membrane expression measured here (40% vs
6%), in link with different antibodies (an anti-rho tag vs conformational antibody). In either
case, the data indicates that the substitution of a proline at position 5.50 does not completely
disrupt the functionality of TSHR.
TSHR activates the Ca2+ pathway in response to TSH [52]. To determine which mutants
can activate this pathway, in a first assay, we measured the Ca2+ accumulation in response to
TSH for all mutants, in cells transfected with the same maximal amount of pcDNA3.1 plasmid
(Fig 7A). Compared to the cAMP pathway with EC50 around 0.2 mUI/ml, the activation of the
Ca2+ pathway by the wild type receptor required a five-fold higher concentration of TSH (Fig
7A). Activation to about half the maximum activity of WT was observed only for the highly
expressed L2.59 mutant. No significant activation could be detected for the other mutants. Sub-
sequently, in a second assay, we measured the Ca2+ accumulation in response to TSH for the
WT control and single mutants (except L2.58P) with comparable cell surface expression (Fig
7B). In these conditions, we did not observe significant Ca2+ accumulation in response to TSH
for any of the mutants.
Fig 6. Constitutive cAMP activity of TSHRmutants. Typical measurements of the constitutive activity of
the L2.58P (a), L2.59P (b), I2.60P (c) and A5.50P (d) TSHRs. In each panel, the cAMP accumulation
obtained in the presence of the mutated andWT TSHR is indicated by open and closed symbols,
respectively.
doi:10.1371/journal.pone.0142250.g006
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Dynamic homology modelling supports a bulged TM2 and a straight TM5
In our set of TSHR mutants, the substitution of a proline residue at position 2.59 does not
impair complex glycosylation and membrane expression, indicating that this mutation is less
deleterious for receptor folding and/or processing than proline substitution at positions 2.58
and 2.60. This is consistent with the favoured positioning of proline at position 2.59 in bulged
TM2 [17]. Our data thus supports a model for the transmembrane domain of TSHR with
bulged TM2 and “unbulged” TM5. However, whether TM5 is straight or maintains a kinked
structure could not be determined from experimental data. We thus modeled the transmem-
brane domain of TSHR with a kinked TM5 and assessed the stability of this structure by molec-
ular dynamics simulations. This procedure is an efficient method to validate homology models
[28]. The modelling protocol maintained the bulged structure of TM2 present in the OX2 tem-
plate, but forced the deletion of one residue at position 5.45 in the TM5 bulge of OX2 (see
alignment in Fig 8). As a result, the initial TSHR model presented a marked kink in TM5 with
a bend angle of 26°, similar to the bend angle of the template. Then we performed MD simula-
tions in an explicit membrane environment. The initial model and relevant snapshots are avail-
able as Supporting Information (S3 File).
Fast reorganisation of the TSHR transmembrane domain with RMSD of about 2.0 Å
occurred in the first 100 ps of the equilibration phase, and was followed by slower reorganisa-
tion in the next 10 ns (Fig 9A). A first plateau around 2.5 Å was stable up to 35 ns, and then a
transition led to a second plateau around 3 Å. The transition was concomitant with rotameric
Fig 7. TSH induced Ca2+ response of TSHRmutants. Typical dose-response curves of Ca2+ accumulation induced by TSH on HEK-293 cells transfected
with pcDNA3.1 plasmids encodingWT or mutated TSHR. In (a), the cells were transfected with the same amount of TSHR coding plasmids, yielding the
membrane expression shown in insert. In (b), the cells were transfected with different amounts of TSHR coding plasmids to obtain similar levels of cell
surface expression, shown in insert. The total amount of pcDNA3.1 plasmids was kept constant by addition of empty plasmids. Receptor symbols: closed
circles, WT; closed down triangles, L2.58P; open squares, L2.59P; open triangles, I2.60P; closed diamonds, A5.50P; closed squares, L2.58PA5.50P; closed
triangles, P2.59PA5.50P; open diamonds, I2.60PA5.50P.
doi:10.1371/journal.pone.0142250.g007
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reorientation of the E3.37 and N5.47 side chains that led to H-bond interactions between these
two residues (Fig 8C). A major reorganisation of TM5 occurred at the very beginning of the
equilibration phase. During the minimisation steps, the bend angle of TM5 decreased from 26°
to about 10° and resulted in the straightening of the helix. Thereafter, TM5 was stable during
the remainder of the simulations, with an angle of 9° ± 5° between the N- and C-termini (Fig
9B). Nevertheless, during the equilibrium phase, the i to i-4 H-bonding pattern was not regular
(Fig 9D). During the first plateau, some irregularities were still observed, whereas, during the
second plateau, the helical pattern was very stable, suggesting that the interaction between the
side chains of E3.37 and N5.47 stabilizes the structure of TM5. The initial bend angle of TM2
was 33°. It decreased during the equilibrium phase, along with a reorganisation of the helix
Fig 8. Dynamicmodelling of the TSHR transmembrane domain. (a) Cartoon representation of TSHR transmembrane domain, obtained by homology
modelling with the OX2 template, before and after simulations. The initial model is green. The snapshots obtained after 10, 20, 40 and 60 ns MD simulations
are white, slate, grey and purple, respectively. The ovals indicate the positions of the distortions in TM2 and TM5. (b) TM2 (left) and TM5 (right) of the OX2
template (magenta) superimposed with the initial TSHRmodel (green) and with the snapshots obtained after 10 and 40 ns MD simulations (white and grey,
respectively). (c) Close-up view of the relative orientation of the E3.37 and N5.47 side chains in the snapshots obtained after 10, 20, 40 and 60 ns MD
simulations. (d) Sequence alignment between OX2 and TSHR used for homology modelling. The / symbol in the OX2 sequence indicates interruption of the
sequence due to either missing residues in the crystal structure or residues not used for structural constraints in the modelling procedure. Helices are
indicated by grey shading. The residues modeled with helical constraints in ECL1 are in italic. The positions of the anchors are indicated by stars. The
position of the deletion in TM5 of OX2 is red. The positions of the proline substitutions in TSHR are red and underlined.
doi:10.1371/journal.pone.0142250.g008
Insights into the TSHR Transmembrane Domain
PLOS ONE | DOI:10.1371/journal.pone.0142250 November 6, 2015 13 / 20
(Fig 8B), then remained stable at 22° ± 6° (Fig 9B). The backbone i to i-4 H-bond pattern of
TM2 was irregular during the equilibration phase then remained stable during the 60 ns pro-
duction run (Fig 9C). Due to the presence of the bulge, the i to i-4 H-bonds were absent from
positions 2.56 to 2.59, whereas two i to i-5 H-bonds involving positions 2.57 and 2.58 stabilized
the helical distortion.
Discussion
A variety of TM2 and TM5 structures are observed in crystal structures of class A GPCRs and
are usually related to the presence of specific proline patterns [11]. However, in the absence of
proline in these helices, no prediction can be done a priori, since kinks or bulges may be pres-
ent in α-helices in the absence of proline [11, 53]. Our previous analysis of helical distortions
indicates that bulges are stabilized by the presence of a proline residue that can be positioned at
either one of two consecutive positions [12, 13]. For TM2 in class A GPCRs, these two posi-
tions correspond to 2.59 and 2.60 with a marked preference for 2.59, whereas the P2.58 pattern
is not compatible with a bulge [17].
Proline substitutions are not easily accommodated in proteins, except when they induce
only local structural alteration [53]. With the exception of constitutive activity (see below), the
experimental results obtained with the proline substitutions in TM2 of TSHR indicate that the
structural and/or functional impairment ranges in the following order: WT< P2.59< P2.60
<< P2.58. The tolerance for position 2.59 supports the hypothesis that the TM2 distortion in
TSHR results from a vestigial proline at position 2.59 later removed during evolution and thus
corresponds to a bulge. This hypothesis is corroborated by such a vestigial P2.59 proline in the
Fig 9. Analysis of the MD simulations of the TSHR transmembrane domain. (a) Time evolution of the root mean squared deviations (RMSD) of the Cα
atoms of the TSHR transmembrane domain (grey) or transmembrane helices only (blue). The insert shows the evolution of the distance between the Cδ
atom of E3.37 and the Nδ1 atom of N4.47; (b) Time evolution of the bend angle of TM2 (grey) and TM5 (blue); (c) Backbone i to i-4 (closed symbols) and i to i-
5 (open symbols) H-bonds in TM2. The percent of H-bonds was measured during the equilibration phase (triangles) and the production run (circles); (d)
Backbone i to i-4 H-bonds in TM5 during the equilibration phase (triangles), the 35 first ns (squares) and the 25 last ns (circles) of the production run.
doi:10.1371/journal.pone.0142250.g009
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closely related follitropin receptor fromM. auratus (Uniprot # Q6R6L8). Moreover, the MD
simulations of the TSHR model suggest that position 2.59 is not involved in either i to i-4 or i
to i-5 backbone H-bonds. This is not the case for position 2.60 involved in i to i-4 H-bonds.
This difference in H-bonding is consistent with the observed preference of TSHR for proline
substitution at position 2.59 rather than 2.60, since proline cannot be engaged in H-bond with
preceding carbonyl groups.
Concerning TM5, the evolutionary analysis carried out in this study strongly supports a
deletion of one residue in TM5, consistent with the straight structure previously proposed by
Kleinau et al., based on constitutive activity of L5.44A mutant [27]. In both studies, the data
indicates that the substitution of a proline at position 5.50 does not completely disrupt the
functionality of TSHR. This might be related to the external position of TM5 and the absence
of steric constraints allowing local conformational changes to adapt to the mutation.
How does the proposed structure of the TSHR transmembrane domain help rationalize the
effect of the mutations on the receptor functionality? The activation of TSHR depends on a switch
involving D6.44 in TM6 and N7.49 in TM7 [54, 55]. The high constitutive cAMP activity of WT
TSHR indicates a low activation energy barrier between the active and inactive states [56] and
consequently it is very sensitive to mutations [57]. Position 2.46 has an important role in the equi-
librium between active and inactive states, since the L2.46Amutation increases the constitutive
activity of TSHR by a factor of 13 [55]. The marked decrease in the constitutive activity of the
L2.59P and L2.60P mutants (Fig 6 and Table 1) suggests an indirect effect of these substitutions
on the switch that might occur via L2.46. The decrease in the constitutive activity of the A5.50P
mutation might result from an effect on the E3.37—N5.47 H-bond and, in turn, on the D6.44—
N7.49 switch since the distance between the Cα atoms of N5.47 and D6.44 is only 9 Å. Alterna-
tively, the proline mutations might hinder the protein flexibility necessary for activation [56].
By contrast with the other mutants, the L2.58P mutant displays a robust constitutive activity
and disruption of inducible activity (Figs 5 and 6). A spontaneously occurring L2.57P mutation
presents the same phenotype [58]. This suggests that a part of these receptors might be in an
active-like state, and, consequently, would be unable to elicit further response to TSH. A bulged
structure similar to that observed in TM2 of GPCRs is not possible with a proline residue at
position 2.58 or 2.57 [12, 13, 17]. The P2.58 and P2.57 mutations might thus induce either a
reorientation of TM2 or a kink with a frameshift in the extracellular half of TM2 [17], modify-
ing the interaction between the extracellular loops, the hinge region and the ectodomain. The
ectodomain acts as an inverse agonist whose inhibitory effect is released by hormone binding
[29]. The P2.58 mutation might thus either hinder the inhibitory effect of the ectodomain or
alter the D6.44 –N7.49 switch in the mutants able to reach the cytoplasmic membrane.
Upon thyrotropin binding, TSHR activates both Gs and Gq/11 pathways [59, 60]. Ca2+
accumulation results mainly from the Gq/11 pathway [61]. However, this pathway is not the
primary signaling pathway and requires higher TSH concentrations [62], in agreement with
our results (Figs 5 and 7). Numerous mutations that affect the Gq but not the Gs pathway have
been reported [63–65] and are consistent with a reduced affinity of TSHR for Gq as compared
to Gs. We observed a similar effect with proline mutants, since for the same level of expression,
none of the mutants was able to induce significant calcium mobilisation (Fig 7). An elegant
mechanism proposed by Allen et al. to rationalise the difference between Gs and Gq activation
relies on the negative cooperativity of TSH binding to the TSHR dimer [62]. In this model, the
simultaneous occupancy of both G protein binding sites of a TSHR dimer by Gs and Gq would
be necessary for Gq activation. A recent study on TSHR dimerization interface suggests a
broad interface involving TM1 and TM2 on one protomer and TM4 and TM5 on the second
protomer [66]. The position of the proline mutations suggests that they might alter the dimer-
ization interface and, in turn, impair Gq activation. Other explanations that are not mutually
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exclusive would be differential effects of the proline mutations on the affinity of TSHR for Gs
and Gq or an effect of the glycosylation state of TSHR on Gq activation.
Finally, very low membrane and total expression of the double mutants (Fig 3) indicates
impaired and/or slower folding that prevents them from fulfilling quality control for export
and membrane targeting. The synergetic effect of mutations in TM2 and TM5 is striking with
the L2.59PA5.50P mutant. Albeit the L2.59P and A5.50P single mutations do not prevent
TSHR from eliciting a robust cAMP response, the L2.59PA5.50P double mutation is more dele-
terious than the additive effects of the single mutations. This suggests that conformational flex-
ibility allowing the receptor to adapt to a mutation is not limited to the vicinity of the mutated
residue but also involves long range residues.
Conclusions
Experimental data and bioinformatics analysis carried out here strongly supports the assump-
tion that TSHR and related glycoprotein hormone receptors share a common transmembrane
fold, characterized by a bulged TM2 and a straight TM5, with no similar crystal structure
reported yet. In the absence of crystal structure, this analysis provides a better understanding
of structural determinants of the transmembrane domain of TSHR and related receptors,
which should be advantageous in the design of drugs that are targeted towards the internal
binding site of these receptors. The strategy of proline substitution in TM2 and TM5 appears
to be a useful method to help model these helices in GPCRs when no proline can guide model-
ling and no closely related template is available. Modelling these helices with kinked, straight
or bulged conformations alters the residues facing the internal cavity of the receptors. The cor-
rect structural conformation of these helices is thus of crucial importance for drug design.
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